78 related articles for article (PubMed ID: 10725546)
41. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
42. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
[TBL] [Abstract][Full Text] [Related]
43. Persistent infection of MT-4 cells by human immunodeficiency virus type 1 becomes increasingly likely with in vitro serial passage of wild-type but not nef mutant virus.
Nishino Y; Nakaya T; Fujinaga K; Kishi M; Azuma I; Ikuta K
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2241-51. PubMed ID: 7521392
[TBL] [Abstract][Full Text] [Related]
44. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
Buzon MJ; Erkizia I; Pou C; Minuesa G; Puertas MC; Esteve A; Castello A; Santos JR; Prado JG; Izquierdo-Useros N; Pattery T; Van Houtte M; Carrasco L; Clotet B; Ruiz L; Martinez-Picado J
J Antimicrob Chemother; 2012 Jan; 67(1):32-8. PubMed ID: 21994909
[TBL] [Abstract][Full Text] [Related]
45. Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.
Maijgren-Steffensson C; Sönnerborg A; Vahlne A; Britton S; Larsson S; Ahrlund-Richter L
Mol Ther; 2001 Apr; 3(4):531-5. PubMed ID: 11319914
[TBL] [Abstract][Full Text] [Related]
46. Genotypic prediction of resistant mutation in HIV-1 pol gene towards the antiretroviral drugs.
Kumar A; Jadhav C
Int J Bioinform Res Appl; 2011; 7(1):15-23. PubMed ID: 21441094
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.
Labrosse B; Treboute C; Alizon M
J Virol; 2000 Mar; 74(5):2142-50. PubMed ID: 10666243
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
[TBL] [Abstract][Full Text] [Related]
49. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
50. Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.
Yusa K; Song W; Bartelmann M; Harada S
J Virol; 2002 Mar; 76(6):3031-7. PubMed ID: 11861869
[TBL] [Abstract][Full Text] [Related]
51. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.
Doualla-Bell F; Gaseitsiwe S; Ndungú T; Modukanele M; Peter T; Novitsky V; Ndwapi N; Tendani G; Avalos A; Wester W; Bussmann H; Cardiello P; Marlink R; Moffat H; Thior I; Wainberg MA; Essex M
Antivir Chem Chemother; 2004 Jul; 15(4):189-200. PubMed ID: 15457680
[TBL] [Abstract][Full Text] [Related]
52. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades.
Palumbo P; Holland B; Dobbs T; Pau CP; Luo CC; Abrams EJ; Nesheim S; Vink P; Respess R; Bulterys M;
J Infect Dis; 2001 Nov; 184(9):1120-6. PubMed ID: 11598834
[TBL] [Abstract][Full Text] [Related]
53. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
[TBL] [Abstract][Full Text] [Related]
55. Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.
Schätzl H; Gelderblom HR; Nitschko H; von der Helm K
Arch Virol; 1991; 120(1-2):71-81. PubMed ID: 1929879
[TBL] [Abstract][Full Text] [Related]
56. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
[TBL] [Abstract][Full Text] [Related]
57. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
58. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
[TBL] [Abstract][Full Text] [Related]
59. Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.
Gianotti N; Seminari E; Lazzarin A; Boeri E; Clementi M; Danise A; Salpietro S; Fusetti G; Castagna A
AIDS Res Hum Retroviruses; 2005 Jun; 21(6):545-54. PubMed ID: 15989459
[TBL] [Abstract][Full Text] [Related]
60. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
